Drug intelligence / Profile preview

KGEN002

Development stage: Preclinical
Lead developer: KiraGen Bio
Modality: Allogeneic CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies

Overview

KGEN002 is an investigational allogeneic cell therapy being developed by KiraGen Bio for the treatment of glioma (undisclosed subtype). As an allogeneic ("off-the-shelf") therapy, it utilizes cells from healthy donors, which are engineered to target and eliminate tumor cells. This approach aims to overcome the logistical and manufacturing challenges associated with autologous cell therapies. The program is currently in the discovery stage, and the specific molecular targets and cell types (e.g., CAR-T, CAR-NK) have not yet been publicly disclosed.

Other names: KGEN-002KGEN002KGEN 002

Beyond the preview

Go deeper on KGEN002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KGEN002.

Explore the full profile